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ABSTRACT
Metformin is under evaluation as a potential anticancer agent. Expression of 
total and phospho(Thr172)-adenosine monophosphate-activated kinase-α (AMPKα 
and pAMPKα(Thr172) respectively), a main metformin target, was examined in 
radiotherapy treated breast cancers and metformin’s ability to modulate Trx system 
expression and breast cancer radiosensitivity evaluated in vitro. 
AMPKα and pAMPKα(Thr172) expression was assessed using a discovery (n=166) 
and validation cohort (n=609). Metformin’s role in regulating radioresponse, and 
Trx family expression, was examined via clonogenic assays and Western blots. 
Intracellular reactive oxygen species (ROS) levels, cell cycle progression and 
apoptosis were assessed by flow cytometry.
High AMPKα expression associated with improved local recurrence-free 
(P=0.019), relapse-free (P=0.016) and breast cancer-specific survival (P=0.000065) 
and was, from multivariate analysis, an independent prognostic factor from the 
discovery cohort. From the validation cases AMPKα expression associated with 
relapse-free and breast cancer-specific survival in luminal breast cancers. Metformin 
substantially increased radiosensitivity, intracellular ROS levels and reduced Trx 
expression, in luminal breast cancer cells, but had little effect on basal phenotype 
cells. 
In conclusion, high AMPKα expression associates with improved prognosis, 
especially in luminal breast cancer. Metformin preferentially radiosensitises luminal 
breast cancer cells, potentially due to alterations to intracellular ROS levels via 
modulation of Trx family protein expression.
INTRODUCTION
Metformin (1,1-dimethylbiguanide hydrochloride) 
is a biguanide used worldwide to treat type II diabetes and 
pre-diabetic syndromes [1]. The physiological mechanism 
of its action in diabetes is to enhance glucose utilization, 
increase insulin sensitivity and reduce hepatic glucose 
production and free fatty acid utilization [2]. Its primary 
effect is based on interfering with respiratory complex I, 
reducing ATP production [3], and leading to the activation 
of adenosine monophosphate-activated kinase (AMPK) [4, 
5]. Diabetic patients treated with metformin, but not other 
anti-diabetic drugs, have reduced incidence and better 
survival from cancer of many organs, including colorectal, 
liver, pancreatic, rectal, breast, prostate cancer and upper-
tract urothelial carcinoma [6-12]. However, discordance 
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exists in prostate cancer as some retrospective studies have 
reported that metformin use was not associated with risk 
reduction in systemic progression and all-cause mortality 
in patients treated with radical prostatectomy [13-16].
AMPK, a serine/threonine kinase, functions as 
an energy sensor and metabolic master switch, and is 
activated under conditions of increasing cellular AMP:ATP 
ratios, such as hypoxia, heat shock and ischemia [17]. 
AMPK is a heterotrimeric protein composed of a catalytic 
α subunit (63 kDa) and regulatory β (40 kDa) and γ (38 
kDa) subunits. Each is expressed as functionally redundant 
isoforms including α1, α2, β1, β2, γ1, γ2 and γ3, giving 
12 different possible combinations of holoenzyme. 
Upon activation, the α subunit is phosphorylated at the 
Thr172 residue (reviewed in [18]). Activated AMPK 
elevates cellular energy levels by stimulating energy 
producing catabolic pathways and inhibiting anabolic 
energy consuming pathways. AMPK can be activated 
by up-stream proteins including liver kinaseB1 (LKB1) 
[19] and ataxia teleangiectasia mutated (ATM) kinase 
[20]. The activation of AMPK inactivates mammalian 
target of rapamycin (mTOR), a stimulator of cancer cell 
growth and proliferation frequently hyper-activated by 
genetic alterations in cancer [21]. The anti-tumour effects 
of metformin have been shown to be dependent on such 
AMPK activation [22-25], however antineoplastic effects 
may also be independent of AMPK activation with, for 
example, altered NF-kB signalling being implicated [26].
Metformin and AMPK have recently been shown to 
be involved in regulating the radioresponse of cancer cells. 
Metformin radiosensitised FSaII mouse fibrosarcoma 
cells and human breast cancer MCF7 [27], lung cancer 
cells A549 and H1299 [28, 29] and preferentially killed 
cancer stem cells, by activating AMPK and suppressing 
mTOR [27]. AMPK inhibition induced radioresistance 
of lung cancer cells A549 and H1299 in normal culture 
conditions [28], with glucose starvation reversing this 
[30]. AMPK is phosphorylated by irradiation in an 
ATM dependent manner [30], but independent of LKB1 
[28]. Metformin is reported to be involved in redox 
regulation; reducing intracellular reactive oxygen species 
(ROS) levels in primary human aortic endothelial cells 
by upregulating expression of thioredoxin (Trx) via the 
AMPK-FOXO3 pathway [31]. It has also been shown to 
inhibit thioredoxin-interacting protein (Txnip) mRNA as 
well as protein expression in HeLa cells [32].
The Trx system is a central enzyme family that 
regulates intracellular redox homeostasis and plays an 
important role in regulating the effects of irradiation on 
cancer cells [33]. Trx is a central part of the Trx system 
that also includes thioredoxin reductase (TrxR) and Txnip 
[34]. Trx is reduced, into its biologically active form, by 
TrxR in a NADPH-dependent manner and in turn reduces 
oxidized cysteine groups on down-stream proteins [35]. 
Txnip is the negative regulator of Trx, which directly 
interacts with the catalytic active centre to block the 
reducing activity of Trx as well as the interaction between 
Trx and its down-stream factors [36]. 
The aims of this study were to determine the 
expression, and clinical importance, of total- and 
phospho(Thr172)- AMPKα in early-stage invasive breast 
cancer from patients treated with radiotherapy and to 
investigate the effect of metformin on the radiosensitivity 
of different phenotypes of breast cancer cells, assessing 
if changes in redox homeostasis, due to alterations 
in Trx system proteins, played a role in any altered 
radiosensitivity.
RESULTS
AMPKα and pAMPKα(Thr172) staining location 
and frequency – in the discovery cohort
Both pAMPKα(Thr172) and AMPKα demonstrated 
a mixture of diffuse and granular cytoplasmic staining. 
Heterogeneous staining was shown between, as well as 
within, certain tumour cores for both markers, varying 
from weak to intense staining. Cytoplasmic staining of 
both markers was scored: pAMPKα(Thr172) had a median 
H-score of 98, ranging between 0 and 200; and AMPKα 
had a median H-score of 93, ranging between 0 and 
228. Figure 1A and B illustrates the staining pattern for 
both markers. There was a marginal positive correlation 
between both markers (r=0.305, P=0.000084). X-tile 
bioinformatics software was used to obtain an unbiased 
optimal H-score cut-point for each protein based on patient 
outcome, and dichotomised H-scores into low and high 
scores. The cut-point for pAMPKα(Thr172) was 65 with 
30% (48 of 162) of cases having a low score; and the cut-
point for AMPKα was 90 with 49% (80 of 163) of cases 
having a low score. A small number of tissue microarray 
(TMA) cores were not assessed due to missing cores or 
insufficient representative tumour within a core.
Relationship of AMPKα and pAMPKα(Thr172) 
expression with clinicopathological variables and 
clinical outcome – in the discovery cohort
The expression of AMPKα and pAMPKα(Thr172) 
was assessed for association with clinicopathological 
variables in the discovery cohort (Table 1). High 
AMPKα expression was significantly associated with 
smaller tumour size (χ2=3.97, d.f.=1, P=0.046), low 
grade (χ2=28.338, d.f.=2, P=0.000001), low Nottingham 
Prognostic Index (NPI) score (χ2=18.84, d.f.=2, 
P=0.000081) and estrogen receptor (ER) positive status 
(χ2=38.69, d.f.=1, P<0.000001). The expression of 
pAMPKα(Thr172) was not significantly associated with 
any of the clinicopathological variables.
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Table 1: Association between AMPKα protein expression and clinicopathological variables. 
Variable Discovery cohort AMPKα (n=163)
Validation cohort AMPKα 
(n=479)
 Low High P-value Low High P-value
Age (years)       
≤40 3 4 1 22 22 0.017
>40 77 79  140 295  
Size (cm)       
≤2 63 73 0.046 121 257 0.105
>2 17 8  41 60  
Stage       
 I 65 63 0.763 117 235 0.904
 II 13 17  38 69  
III 2 2  7 13  
Grade       
 I 6 25 0.000001 9 59 <0.000001
 II 24 37  42 139  
III 50 19  111 119  
Node status       
Negative 64 62 0.595 112 220 0.982
Positive 16 19  39 77  
NPI       
Good (<3.4) 22 47 0.000081 34 143 0.000001
Intermediate (3.4-5.4) 55 28  109 153  
Poor (>5.4) 3 6  19 21  
Vascular invasion       
Negative 60 65 0.518 113 200 0.109
Positive 20 17  46 114  
ER       
Negative 33 1 <0.000001 70 45 <0.000001
Positive 47 80  90 261  
PgR       
Negative ND   90 87 <0.000001
Positive    62 207  
HER2       
Negative ND   135 277 0.481
Positive    21 35  
Basal phenotype       
Non-basal ND   101 254 0.000003
Basal    52 45  
Classification       
Luminal ND   91 265 <0.000001
Triple negative    55 28  
HER2+    12 11  
The P-values are resultant from the Pearson χ2 test of association. Significant P-values are indicated 
in bold. The discovery and validation cohorts were comprised of 166 and 609 patients respectively; 
however, scores were not available for every patient (163 of 166 in the discovery cohort and 479 of 609 in 
the validation cohort). The number of observations for each cohort is shown for each clinicopathological 
variable; the table does not include the number of observations where clinicopathological data were not 
available. Abbreviations: ND, not determined.
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Kaplan-Meier analysis showed that high AMPKα 
expression was associated with better outcome in terms 
of lower local recurrence risk (P=0.019), longer relapse-
free survival (P=0.016) and breast cancer-specific survival 
(P=0.000065) (Figure 1C), while pAMPKα(Thr172) 
was not associated with breast cancer outcome in this 
cohort. Multivariate Cox regression analysis including 
tumour size, stage (i.e. TNM stage), grade, node status, 
NPI, vascular invasion and ER status (with individual 
Kaplan-Meier statistics of P=0.048, P=0.000079, 
P=0.000025, P=0.019, P=0.000482, P=0.003 and 
P=0.007, respectively), showed that AMPKα expression 
was independently associated with breast cancer-specific 
survival (Hazard Ratio (HR) = 0.16; 95% confidence 
interval (CI) = 0.04-0.63; P=0.009); and such analysis, 
including tumour stage (with individual Kaplan-Meier 
statistics of P=0.001), showed that AMPKα expression 
was also independently associated with relapse-free 
survival (HR = 0.36; 95% CI = 0.15-0.87; P=0.023) (Table 
2). AMPKα expression was not, however, independently 
associated with local recurrence in multivariate analysis 
that included ER status and tumour size (HR = 0.52; 95% 
CI = 0.19-1.43; P=0.206).
Relationship of AMPKα expression with 
clinicopathological variables and clinical outcome 
– in the validation cohort
To verify the finding that AMPKα expression was 
associated with prognosis in early-stage invasive breast 
cancer patients treated by breast-conserving surgery plus 
radiotherapy, an independent patient validation cohort was 
investigated. The staining pattern of AMPKα was similar 
to that of the discovery cohort. The median H-score 
was 145 and ranged between 0 and 300. The X-tile 
determined cut-point was 115 with 34% (162 of 479) of 
cases having a low score. Similar to the discovery cohort, 
high AMPKα expression was significantly associated 
with features of good prognosis including low grade 
(χ2=43.42, d.f.=2, P<0.000001), low NPI score (χ2=27.32, 
d.f.=2, P=0.000001) and ER positive status (χ2=47.68, 
d.f.=1, P<0.000001). High AMPKα expression was 
also associated with some of the additional biomarkers 
available for this cohort, including progesterone receptor 
(PgR) positive status (χ2=36.72, d.f.=1, P<0.000001), 
and basal-phenotype negative status (χ2=21.53, d.f.=1, 
P=0.000003). High AMPKα expression was significantly 
associated with older patients (χ2=5.67, d.f.=1, P=0.017), 
but not with tumour size (Table 1).
Kaplan-Meier survival analysis showed that high 
AMPKα expression was associated with longer breast 
cancer-specific survival (P=0.005, Figure 3A), but not 
with local recurrence-free (P=0.328) or relapse-free 
survival (P=0.057, Figure 2A). In multivariate Cox 
regression analysis, including tumour size, stage, grade, 
node status, NPI, vascular invasion, ER, PgR, human 
epidermal growth factor receptor 2 (HER2) and basal-
phenotype status (with individual Kaplan-Meier statistics 
of P=0.041, P<0.000001, P=0.00002, P=0.000005, 
P<0.000001, P=0.002, P=0.004, P=0.000428, P=0.002 
and P=0.000073, respectively), AMPKα expression was 
not independently associated with breast cancer-specific 
survival in all breast cancer phenotypes (HR = 0.66; 95% 
CI = 0.41-1.07; P=0.089) but significant results were 
obtained with the luminal-phenotype group separately and 
are described below.
Table 2: Multivariate Cox Regression analysis of factors associated with breast cancer-specific survival and 
relapse-free survival for the discovery cohort. 
  Breast cancer-specific survival        Relapse-free survival 
Variable HR 95% CI P-value HR 95% CI P-value
AMPKα expression 0.16 0.04 to 0.63 0.009 0.36 0.15 to 0.87 0.023
Stage 2.24 0.54 to 9.37 0.269 1.17 0.51 to 2.69 0.708
Grade 2.61 0.68 to 10.08 0.164 N/A   
Size (≤ / > 2 cm) 1.48 0.49 to 4.45 0.488 N/A   
Node status (-/+) 0.84 0.09 to 7.72 0.880 N/A   
NPI 1.21 0.24 to 6.17 0.821 N/A   
Vascular invasion 2.19 0.91 to 5.29 0.081 N/A   
ER (-/+) 0.93 0.37 to 2.37 0.882 N/A   
Abbreviation: HR, Hazard Ratio; CI, confidence interval; N/A, not applicable. Significant P-values are indicated 
by bold.
Oncotarget12940www.impactjournals.com/oncotarget
Relationship of AMPKα expression with clinical 
outcome of luminal-phenotype breast cancer – in 
the validation cohort
As AMPKα expression was significantly associated 
with ER, PgR and basal-phenotype status, we further 
investigated the prognostic significance of AMPKα 
expression in different subtypes of breast cancer in the 
validation cohort. As shown in Supplementary Table 
S1, of the 609 patients, 77% (n=453) tumours were of 
luminal-phenotype, 18% were triple-negative (n=108), 
4% (n=26) were HER2+ and 21% (n=117) were basal-
like. High AMPKα expression was associated with 
longer relapse-free survival (P=0.02, Figure 2B) and 
breast cancer-specific survival (P=0.004, Figure 3B) 
in luminal-phenotype tumours. No similar associations 
were identified in the HER2+, basal-like or triple-
negative classes. Multivariate Cox regression analysis 
demonstrated that AMPKα expression was independently 
associated with relapse-free survival (HR = 0.57; 95% 
CI = 0.38-0.86; P=0.008; potential confounding factors: 
stage, node status, NPI, vascular invasion and HER2 with 
individual Kaplan-Meier statistics of P=0.001, P=0.015, 
P=0.000282, P=0.004 and P=0.001, respectively) and 
breast cancer-specific survival (HR = 0.48; 95% CI = 
0.28-0.82; P=0.007; potential confounding factors: stage, 
grade, node status, NPI, vascular invasion, PgR and HER2 
with individual Kaplan-Meier statistics of P<0.000001, 
P=0.000331, P=0.000001, P<0.000001, P=0.002, P=0.01 
and P=0.000005, respectively) in luminal-phenotype 
breast cancer cases when potential confounding factors 
were included (Table 3).
Figure 1: High AMPKα expression was associated with good prognosis in breast cancer in the discovery cohort. 
Representative photomicrographs of negative, weak, moderate and strong staining of (A) AMPKα and (B) pAMPKα(Thr172). 
Photomicrographs are at ×10 magnification with ×20 magnification inset box where scale bar shows 100 μm. (C) Kaplan-Meier analysis of 
local recurrence-free, relapse-free and breast cancer-specific survival showing the impact of AMPKα expression in the discovery cohort of 
166 patients with significance determined using the log-rank test. High AMPKα expression is associated with lower local recurrence risk 
(P=0.019), better relapse-free survival (P=0.016) and breast cancer-specific survival (P=0.000065).
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Metformin sensitises luminal breast cancer cells 
to irradiation but not basal phenotype
As radiotherapy is a crucial component of breast-
conserving therapy, and to take such IHC based expression 
studies forward, we assessed whether metformin, a 
known modulator of AMPK activity could affect the 
radiosensitivity of different breast cancer phenotypes. 
Both MCF7 and MDA-MB-231 cells exhibited similar 
radiosensitivities under control conditions (Figure 4A). 
The IC50 for metformin in both cell lines, determined 
from cell growth curve experiments (data not shown), 
was 10 mM. This drug concentration was used for 
radiosensitivity studies and was initially assessed for 
drug alone cytotoxicity using clonogenic survival. As 
shown in Figure 4B, metformin exhibited significant 
cytotoxicity to both cell lines; with an increased level of 
cytotoxicity observed with the basal-like breast cancer 
MDA-MB-231 cells (surviving fraction (SF)=21.75% 
of control, P<0.01) compared to the luminal MCF7 
cells (SF=59.14% of control, P<0.01). Interestingly, the 
radiosensitisation effect of metformin did not parallel its 
cytotoxic effect. Metformin caused little change in the 
radiosensitivity of MDA-MB-231 cells but a substantial 
increase in radiosensitivity of MCF7 cells (sensitiser 
enhancement ratio (SER) =1.5 at 1% SF) (Figure 4C). The 
SF at 6 Gray (Gy) for MCF7 cells treated with metformin 
in combination was 0.03% but 0.55% for radiation alone 
(P<0.01, Figure 4C).
Figure 2: Kaplan-Meier analysis of relapse-free 
survival showing the impact of AMPKα expression in 
the validation cohort of 609 patients with significance 
determined using the log-rank test. (A) AMPKα expression 
is not associated with relapse-free survival in the whole cohort 
(P=0.057). (B) High AMPKα expression is associated with a low 
risk of disease relapse in luminal breast cancer subgroup (n=453, 
P=0.020), but not in (C) triple-negative (n=108, P=0.352), (D) 
HER2+ (n=26, P=0.399), and (E) basal-like (n=117, P=0.959) 
breast cancer subgroups.
Figure 3: Kaplan-Meier analysis of breast cancer-
specific survival showing the impact of AMPKα 
expression in the validation cohort of 609 patients 
with significance determined using the log-rank test. 
(A) High AMPKα expression is associated with a low risk of 
breast specific death in the whole cohort (P=0.005) and in (B) 
luminal breast cancer subgroup (n=453, P=0.004), but not in (C) 
triple-negative (n=108, P=0.443), (D) HER2+ (n=26, P=0.257), 
or (E) basal-like (n=117, P=0.756) breast cancer subgroups.
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Table 3: Multivariate Cox Regression analysis of factors associated with breast cancer-specific survival 
and relapse-free survival for luminal phenotype disease in the validation cohort.
 Breast cancer-specific survival      Relapse-free survival 
Variable HR 95% CI P-value HR 95% CI P-value
AMPKα expression 0.48 0.28 to 0.82 0.007 0.57 0.38 to 0.86 0.008
Stage 3.60 1.75 to 7.42 0.001 2.62 1.38 to 4.97 0.003
Grade 1.71 0.88 to 3.33 0.114 N/A   
Node status (-/+) 1.07 0.48 to 2.42 0.863 0.66 0.29 to 1.48 0.310
NPI 0.82 0.36 to 1.86 0.633 0.85 0.57 to 1.28 0.435
Vascular invasion 1.53 0.90 to 2.63 0.119 1.68 1.12 to 2.51 0.011
PgR (-/+) 0.51 0.29 to 0.90 0.020 N/A   
HER2 (-/+) 2.59 1.28 to 5.25 0.008 2.12 1.22 to 3.70 0.008
Abbreviation: HR, Hazard Ratio; CI, confidence interval; N/A, not applicable. Significant P-values are 
indicated by bold.
Figure 4: Effects of metformin on survival and radioresponse of breast cancer cell lines. (A) Luminal MCF7 and basal-like 
MDA-MB-231 breast cancer cells were subjected to single dose irradiation and compared with sham irradiated cells (0 Gy) as control. 
Clonogenic assay was performed to assess the surviving fraction of cells. (B) Both cell lines were treated with 10 mM of metformin for 
48 hours (cells without metformin treatment as control), and clonogenic assays were performed to assess the surviving cells. Values were 
plotted as percentage of control. (C) MCF7 and MDA-MB-231 cells after metformin treatment were subjected to single dose irradiation, 
and clonogenic assay was used to assess the surviving cells. PEs for MDA-MB-231 and MCF7 cells in clonogenic assay were 52.83% 
(± 7.43%) and 30.33% (± 6.30%), respectively. Data represent the mean ± SD of three independent experiments, with each experiment 
containing six parallel data sets. *P<0.05, **P<0.01 vs. control.
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Metformin elevated intracellular ROS production 
in luminal breast cancer cells but not basal 
phenotype
To explore the reason for the differential 
radiosensitising effects of metformin on breast cancer 
cells, intracellular ROS levels were assessed by flow 
cytometry. As shown in Figure 5A H2O2 induced ROS to 
a similar level in both lines but after metformin treatment, 
intracellular ROS levels were elevated to 4- fold of control 
in MCF7 cells (P<0.05), with no significant alterations in 
MDA-MB-231 cells (P>0.05). 
As radiosensitivity can be influenced by the mode of 
cell death and by perturbations in cell cycle distribution, 
flow cytometry assessments of apoptosis and the cell 
cycle were conducted. As shown in Figure 5B and 5C, 
metformin had no effect on either cell cycle or apoptosis 
of MCF7 cells. In MDA-MB-231 cells, metformin induced 
a slight increase in the percentage of necrotic cells (1.94 
-fold of control, P<0.05, Figure 5C), however it did not 
affect the apoptotic or cell cycle response of this line.
Metformin differentially regulates expression of 
Trx family proteins in breast cancer cells
Western blot analysis of Trx, TrxR and Txnip was 
conducted to assess whether any altered ROS homeostasis 
by metformin might involve the Trx system. The 
endogenous expression levels of Trx and Txnip were lower 
in MCF7 than in MDA-MB-231, whilst TrxR expression 
was similar. Metformin decreased Trx expression levels in 
MCF7 but had no effect on MDA-MB-231 cells. In both 
cell lines, expression of Txnip was dramatically attenuated 
by metformin treatment. TrxR expression was not affected 
by metformin treatment in either cell line (Figure 5D).
DISCUSSION
Retrospective studies have found that use of the 
antidiabetic drug metformin in diabetic patients’ results in 
a reduced incidence of, and better survival from, breast 
cancer [12, 37-39]. However, in a randomized pre-surgical 
trial including 200 non-diabetic breast cancer patients, no 
alteration to tumour proliferation, as assessed by Ki67, 
was observed [40]. Metformin has been reported to be 
involved in regulating the radioresponse of a number 
of different cancer cell types, including breast cancer, 
in an AMPK-dependent manner [27-29, 41]. In order to 
assess the possible value of metformin as a sensitiser for 
radiotherapy of breast cancer and AMPK as a potential 
prognostic factor, the present study first sought to evaluate 
the expression of AMPK, the target of metformin, in 
radiotherapy treated early-stage invasive breast cancer 
patients. Similar to others [42], the current study did 
not observe any association between pAMPKα(Thr172) 
Figure 5: Effects of metformin on ROS level, cell cycle, 
apoptosis, and expression of Trx system proteins in 
breast cancer cell lines. (A) Flow cytometry analysis of 
intracellular ROS level of MCF7 and MDA-MB-231 breast 
cancer cells treated with 10 mM metformin (Met) for 48 hours, 
positive control (H2O2) and negative control cells. MFIs were 
calculated and plotted as fold change of control. Cells treated 
with 10 mM metformin for different period of time as indicated 
(72 hours means that cells were treated with metformin 
for 48 hours and spared for extra 24 hours) were subject to 
flow cytometry analysis of (B) cell cycle and (C) apoptosis. 
Percentages of cells were calculated and presented as mean ± SD 
of three independent experiments. *P<0.05 vs. control. (D) Cells 
were treated with 10 mM metformin for 48 hours (cells without 
treatment as control). Western blot was performed to assess 
the expression of Trx (MW=12KDa), TrxR (MW=55KDa) and 
Txnip (MW=50KDa) in cells, with β-actin (MW=42KDa) as 
internal control. Experiments were repeated three times and the 
representative blots are presented.
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expression and prognosis. However, when total-AMPKα 
expression was assessed, in two independent patient 
cohorts, expression was associated with patient prognosis. 
The reason why total-AMPKα but not pAMPKα(Thr172) 
associated with prognosis is uncertain, but may be due 
to the differential phosphorylation patterns that can 
occur with AMPK: in addition to Thr172 AMPKα is also 
phosphorylated at Thr258 and Ser485 for AMPKα1 and 
Ser491 for AMPKα2 [43], expression of pAMPKα at 
other phosphorylation sites, rather than Thr172, may be 
important for breast cancer prognosis, and should perhaps 
be addressed in future work.
Although pAMPKα(Thr172) expression has 
been previously studied using immunohistochemical 
approaches, total-AMPKα has rarely been assessed. 
Small studies in thyroid and breast cancer measured 
levels between normal and cancerous tissue [44, 45] 
but the current study is the first of its type to determine 
associations with clinical outcomes. In both the discovery 
and validation cohorts, high AMPKα expression was 
significantly associated with low grade, low NPI score 
and ER positive status, all of which are indicative of 
better prognosis. High AMPKα expression was associated 
with patient age in the validation cohort but not in the 
discovery cohort. The age distribution was, however, 
different in these two cohorts: the age of patients in the 
discovery cohort ranged from 31 to 70 vs. 18 to 72 in the 
validation cohort; and the number of patients aged 40 or 
less occupied 8% of the whole population in the validation 
cohort, which is nearly twice of that in the discovery 
cohort (4.2%). AMPKα expression was associated 
with two additional clinicopathological variables in 
the validation cohort: PgR and basal-phenotype status; 
these clinicopathological variables were not available for 
the discovery cohort. The association of high AMPKα 
expression with ER, PgR positive and non basal-like 
tumours may indicate differential expression of AMPKα 
in different breast cancer phenotypes and requires further 
verification.
High AMPKα expression was associated with lower 
local recurrence risk, better relapse-free and breast cancer-
specific survival. In multivariate Cox regression analysis 
AMPKα significantly associated with relapse-free and 
breast cancer-specific survival independent of possible 
confounding factors in the discovery cohort. AMPKα 
expression was significantly associated with breast cancer-
specific survival in the validation cohort. As AMPKα 
expression was related to breast cancer phenotype, the 
importance of AMPKα expression in prognosis of different 
subtypes of breast cancer was assessed in the validation 
cohort. Interestingly, high AMPKα expression associated 
with better relapse-free and breast cancer-specific survival 
and in multivariate Cox regression analysis AMPKα 
expression was also independently associated with 
relapse-free and breast cancer-specific survival in luminal 
phenotype breast cancer. Our study is the first to examine 
the expression of total-AMPKα in breast cancer tissue and 
to report on its prognostic significance in radiotherapy 
treated breast cancer, especially in luminal phenotype 
disease. 
Interestingly, such phenotype preference is also 
observed in the tumour inhibitory effects of metformin, 
the activator of AMPK, in breast cancer patients. 
Retrospective studies have shown that metformin use is 
associated with improved breast cancer-specific survival 
of diabetic women with luminal [38] and HER2+ breast 
cancers [39], but did not significantly impact survival 
outcomes in diabetic patients with triple-negative breast 
cancer [46]. As a result, we further assessed the effect of 
metformin on the radioresponse of different phenotypes of 
breast cancer in-vitro. Luminal breast cancer MCF7 and 
basal-like breast cancer MDA-MB-231 cells were used 
in this study, and when treated by single-dose irradiation 
both lines exhibited a similar response. However, when 
metformin treatment was combined with irradiation, a 
substantial increase in radiosensitivity of MCF7 cells 
was observed, with an SER of 1.5, but with little effect 
on the radiosensitivity of MDA-MB-231 cells. Such 
results suggest a possible phenotype related mechanism of 
action for metformin, which can apparently radiosensitise 
luminal phenotype cells but has limited effect on basal 
phenotype breast cancer. 
To explore the mechanisms of this interesting 
phenomenon, alterations to redox homeostasis were 
assessed by examining the change in ROS levels following 
metformin treatment. Intracellular ROS production is the 
major mediator for low-LET radiation-induced cell killing 
in radiotherapy [47]. Metformin induced a significant 
increase of ROS levels in luminal breast cancer MCF7 
cells but had no effect in basal-like breast cancer MDA-
MB-231 cells. The differential effects of metformin on 
ROS production in luminal vs. basal-like breast cancer 
cells may provide a potential explanation for its phenotype 
preference in radiosensitisation. Others have reported 
upon metformin regulating intracellular ROS levels 
but with contradictory findings: metformin reduced the 
intracellular ROS level in human aortic endothelial cells 
[31]; but elevated it in primary human fibroblasts [48], 
which, together with our results, suggest that the effect of 
metformin in regulating intracellular ROS production may 
be largely dependent upon the intrinsic characteristics of 
the different cell types, with no uniform pattern. Current 
work suggests that the radiosensitisation effects of 
metformin were not attributable to it altering cell cycle 
progression or the level of apoptosis. Others have shown, 
however, that AMPK deficient cells are radioresistant and 
that such resistance is linked to cell cycle progression and 
proliferation [49].
Cells have a number of systems available to 
regulate intracellular ROS production and maintain 
redox homeostasis including the Trx system [33], which 
has been shown to be associated with clinical outcome 
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in radiotherapy treated early stage breast cancer [50]. 
We performed Western blots to analyse the expression 
changes of Trx family proteins in metformin treated 
cells: metformin decreased the Trx expression level in 
MCF7 cells but had no effect on MDA-MB-231 cells. 
Interestingly, Hou et al. demonstrated that metformin 
inhibited intracellular ROS by upregulation of Trx 
expression via the AMPK-FOXO3 pathway in human 
aortic endothelial cells [31], whilst the current study 
shows the opposite in breast cancer MCF7 cells, with 
metformin increasing ROS production by decreasing Trx 
expression. There are probably many factors responsible 
for such conflicting results, including the concentration 
and duration of metformin exposure (i.e. 250 μM for 24 
hours in the endothelial study vs. 10 mM for 48 hours 
in the current work), and the particular cell line used; 
however, both studies show the importance of Trx in 
metformin regulated ROS production. It is also interesting 
to note the effect of metformin on Txnip, with metformin 
totally abrogating its expression in both cell lines, which is 
consistent with previous reports suggesting that metformin 
inhibits Txnip expression in human hepatocellular 
carcinoma HepG2 and cervical cancer HeLa cells [32], as 
well as rat insulinoma INS-1E beta-cells [51].
In summary, the present study shows that high 
AMPKα expression is associated with a better prognosis 
of early-stage invasive breast cancer patients treated 
by breast-conserving surgery and radiotherapy in two 
independent cohorts. This result was more apparent 
in luminal phenotype disease with further in-vitro 
characterisations showing that metformin, the activator of 
AMPK, induced ROS production in luminal breast cancer 
cells possibly through altered Trx system expression; with 
little effect in basal phenotype cells. Although further 
confirmation is required, both in-vitro and in-vivo, current 
results suggest that metformin may be a clinically effective 
radiosensitiser and that its use should potentially be 
focused on patients with luminal phenotype breast cancer.
MATERIALS AND METHODS
Clinical samples
This study is reported according to REMARK 
(Reporting Recommendations for Tumour Marker 
Prognostic Studies) criteria [52]. Ethical approval for 
the study was granted by Nottingham Research Ethics 
committee 2 under the title “Development of a molecular 
genetic classification of breast cancer” (C202313). Two 
independent cohorts were used; a discovery cohort of 
166 cases and a validation cohort of 609 cases. Both 
cohorts were comprised of primary operable early-
stage (stage I-III) invasive breast cancers from patients 
treated by breast-conserving surgery (wide local 
excision) and radiotherapy at Nottingham University 
Hospitals. Information on clinical history and outcome 
is prospectively maintained and patients were assessed 
in a standardised manner for clinical history and tumour 
characteristics (see Supplementary Table S1). Breast 
cancer-specific survival was defined as the time interval 
(in months) between the date of primary surgery and death 
resultant from breast cancer; local recurrence-free survival 
was defined as the time interval (in months) between the 
start of primary treatment and date of first histological 
confirmation of recurrent cancer (invasive or in-situ) at 
any site within the treated breast; relapse-free survival was 
defined as the time interval (in months) between the start 
of primary treatment and date of disease relapse.
The 166 cases in the discovery cohort were selected 
from all of the early-stage primary operable invasive 
breast cancer patients treated by wide local excision and 
radiotherapy at Nottingham University Hospitals between 
1998 and 2006. The selection scheme was based on the 
local recurrence cases in a chronologic order, where every 
local recurrence case was included in the study: when a 
case with local recurrence was chosen, the immediate 
following 5 suitable cases without local recurrence were 
included. The median age at diagnosis of this cohort 
was 56 years (ranging from 31 to 70) and 78% (130 of 
166) of patients had stage I disease. The follow-up time 
was 171 months (median follow-up time 108 months). 
Supplementary Table S1 shows the full clinicopathological 
characteristics of this cohort.
The 609 samples in the validation cohort were 
chosen from a well-characterised consecutive series of 
early-stage invasive breast cancer patients treated at 
Nottingham University Hospitals, between 1986 and 1998. 
From the initial whole series (n=1802), cases treated by 
wide local excision plus radiotherapy were selected 
(n=609). The median age of the validation cohort was 54 
years (ranging from 18 to 72) and 74% (449 of 609) of 
patients had stage I disease. The follow-up time was 247 
months (median follow-up time 134 months). Data on a 
wide range of biomarkers was available (Supplementary 
Table S1); estrogen receptor (ER), progesterone receptor 
(PgR), human epidermal growth factor receptor 2 (HER2) 
and basal phenotype status were available for this cohort 
and have been described previously [53, 54], with basal 
phenotype being defined as cytokeratin (CK)-5/6 and/
or CK-14 positivity [55]. Current cases were classified 
into three molecular subgroups: ER and/or PgR positive 
(regardless of HER2 status) was defined as luminal; ER, 
PgR and HER2 negative was defined as triple-negative; 
and ER and PgR negative plus HER2 positive was defined 
as HER2+ [56].
Patient treatment, tissue microarray (TMA) 
construction and immunohistochemistry (IHC) are 
described in Supplementary Materials and Methods.
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Cell culture
Two human breast cancer cell lines: MCF7 (luminal 
subtype), MDA-MB-231 (basal subtype) were used in this 
study (both were from American Type Culture Collection). 
All cell lines were cultured at 37˚C in a humidified 
incubator with 5% CO2. MCF7 (passage window 15) 
were maintained in RPMI1640 (Sigma, Dorset, UK) 
supplemented with 10% iron supplemented donor calf 
serum (PAA laboratories, Austria) and 1% penicillin/ 
streptomycin (Sigma). MDA-MB-231 (passage window 
15) were maintained in minimal essential medium EAGLE 
(Sigma) supplemented with 0.1 mM non-essential amino 
acids solution (Sigma), 2 mM L-glutamine(Sigma), 1% 
penicillin/ streptomycin and 10% iron supplemented donor 
calf serum. 
Cell irradiation and clonogenic survival assay
Cells were sub-confluent at irradiation. X-ray-
irradiation was conducted using an RS225 Xstrahl X-ray 
cabinet irradiation system (Xstrahl Limited, UK) with 
a single dose of 1, 2, 4 or 6 Gray (Gy). X-rays were 
delivered at 195 kV, 10 mA, with a dose rate of 0.87 Gy/
min. The cabinet was fitted with a 0.5 mm copper filter 
and used at a 48.4 cm focus-to-skin distance. Sham 
irradiated cells were used as controls. Cells were exposed 
to 10 mM of metformin (BioVision, Milpitas, CA) for 
48 hours prior to irradiation. Cells were then trypsinised 
and plated for clonogenic survival assay with six parallel 
sets. After 18 days colonies were fixed (50% methanol 
in 0.9% saline solution for 15 min followed by methanol 
for another 15 min), stained (0.5% crystal violet) and 
counted as a survivor if containing more than 50 cells. 
Surviving fraction (SF) was calculated as: number of 
colonies / (number of cells plated × plating efficiency), 
where plating efficiency (PE) was defined as: number of 
control colonies obtained / number of control cells plated. 
The sensitizer enhancement ratio (SER) was calculated as 
the radiation dose yielding 1% SF divided by the radiation 
dose giving the same survival where cells were treated 
with metformin.
Measurement of intracellular ROS levels
Sub-confluent cells were treated with 10 mM 
metformin for 48 hours or, as a ROS positive control, 1 
mM of H2O2 for 1 hour then further incubated with the 
membrane permeable dye 2’,7’-dichlorodihydrofluorescein 
diacetate (H2DCF-DA, Sigma) in fresh medium at a final 
concentration of 1 μM for 30 min, at 37˚C. Cells were 
then collected and intracellular ROS levels assessed by 
measurement of the fluorescence (excitation 500 and 
emission 520 nm respectively) using a Beckman Coulter 
FC500 MCL flow cytometer system (Beckman, USA). 
Data exported from the flow cytometer were analysed 
using FlowJo7.6.1 software (Tree Star) to obtain the 
median fluorescence intensity (MFI) of each group. 
Protein extraction and Western blot
Sub-confluent cells, following incubation with 
10 mM metformin for 48 hours, were harvested and re-
suspended in RIPA buffer (Sigma) supplemented with 
protease inhibitor cocktail (Sigma) . A Bio-Rad protein 
assay kit (Bio-Rad Laboratories, USA) was used to 
determine the protein concentration of each sample. 
Lysates were separated by SDS-PAGE and transferred 
onto a nitrocellulose membrane. After blocking with 5% 
(w/v) milk powder in 0.1% PBS/Tween, the nitrocellulose 
membrane was incubated with primary antibody at 4°C 
overnight. The primary antibodies used in this study were: 
goat anti- human Trx antibody (1:1000 dilution; American 
Diagnostica, Stamford, CT), mouse anti- human TrxR 
antibody [19A1] (1:2000 dilution; Abcam, Cambridge, 
UK) and mouse anti- human Txnip antibody (1:1000 
dilution; MBL International Corporation, Woburn, USA). 
HRP-conjugated β-actin antibody (Invitrogen) was used 
as internal control. Membranes were developed with 
Amersham ECL reagent (GE Healthcare, UK). 
Cell cycle analysis
Sub-confluent cells were treated with 10 mM 
metformin for 24 or 48 hours, or treated with metformin 
for 48 hours and spared for an extra 24 hours (72 hours), 
then collected and fixed in 70% ethanol in PBS overnight. 
Fixed cells were then stained using a PBS solution 
containing 2.5 μg/ml of propidium iodide and 200 μg/
ml of RNase for 30 min at 37°C and analyzed using a 
Beckman Coulter FC500 MCL flow cytometer system 
(Beckman, USA).
Annexin V-FITC apoptosis assay
Sub-confluent cells were treated with 10 mM 
metformin for 4, 8, 24 or 48 hours. Apoptosis of cells 
was then assessed by using an annexin V-FITC apoptosis 
detection kit (Invitrogen) according to the manufacturer’s 
instructions and analyzed using a Beckman Coulter FC500 
MCL flow cytometer system (Beckman, USA).
Statistical Analysis
The relationship between categorised protein 
expression and clinicopathological variables was assessed 
using the Pearson Chi Square (χ2) test of association 
or Fishers Exact test if a cell count was less than five. 
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Spearman rank order correlations were performed to 
test the association between expression of AMPKα 
and pAMPKα(Thr172). Survival curves were plotted 
according to the Kaplan-Meier method and significance 
determined using the log-rank test. Multivariate survival 
analysis was performed by the Cox proportional hazards 
regression model and included only those parameters 
that were significant in univariate analysis. Data from in-
vitro experiments were expressed as the mean ± standard 
deviation (SD) and analysed using the Student t-test and 
ANOVA one-way tests. All differences were deemed 
statistically significant at the level of P<0.05. Statistical 
analysis was performed using SPSS 21.0 software (IBM, 
Armonk, NY).
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